Compare CBLL & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBLL | VOR |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 935.3M | 1.1B |
| IPO Year | 2024 | 2021 |
| Metric | CBLL | VOR |
|---|---|---|
| Price | $27.56 | $20.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $31.57 | ★ $39.00 |
| AVG Volume (30 Days) | 647.2K | ★ 715.9K |
| Earning Date | 11-03-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.93 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,063,000.00 | N/A |
| Revenue This Year | $29.72 | N/A |
| Revenue Next Year | $27.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.09 | N/A |
| 52 Week Low | $11.75 | $6.50 |
| 52 Week High | $28.89 | $26.00 |
| Indicator | CBLL | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 52.13 |
| Support Level | $22.96 | $17.44 |
| Resistance Level | $28.11 | $20.11 |
| Average True Range (ATR) | 1.67 | 1.20 |
| MACD | -0.11 | 0.13 |
| Stochastic Oscillator | 81.38 | 55.69 |
CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.